|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- July 13, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Addex Pharmaceuticals Inc., of Geneva, achieved a second preclinical milestone in its partnership with Merck & Co., of Whitehouse Station, N.J., and will receive $500,000. The firm was able to show the desired non-dopaminergic activity profile after oral administration of metabotropic glutamate receptor 4-positive allosteric modulator in an animal model of Parkinson's disease. The collaboration is focused on developing allosteric modulators that activate mGluR4 for Parkinson's disease and other undisclosed indications. Addex received $250,000 after achieving the first preclinical milestone during the first quarter of last year. (See BioWorld Today, Jan. 4, 2008.)
...
Related newspaper, magazine, and journal articles:
|
|
Article: TARGETING A SLICE OF MARKET HELD BY AMGEN TRANSKARYOTIC, HOECHST ...
BIOWORLD Today;
September 30, 1998 ;
700+ words
... ... Oaks, Calif., in April 1997. The case was administratively closed in April 1998 but could be reopened later. (See BioWorld Today, April 17, 1998, p. 1.) Hoechst, of Frankfurt, Germany, is responsible for all development, clinical work ...
|
|